Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.

de Bruyn G, Wang J, Purvis A, Ruiz MS, Adhikarla H, Alvi S, Bonaparte MI, Brune D, Bueso A, Canter RM, Ceregido MA, Deshmukh S, Diemert D, Finn A, Forrat R, Fu B, Gallais J, Griffin P, Grillet MH, Haney O, Henderson JA, Koutsoukos M, Launay O, Torres FM, Masotti R, Michael NL, Park J, Rivera-Medina DM, Romanyak N, Rook C, Schuerman L, Sher LD, Tavares-Da-Silva F, Whittington A, Chicz RM, Gurunathan S, Savarino S, Sridhar S, VAT00002 booster cohorts study team

Open source

DOI
10.1016/j.eclinm.2023.102109
Published
2023 Aug
Container
EClinicalMedicine
Publisher
Not recorded
Open access
yes

Credibility signals

limited evidence Score 45/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

Cite this work

BibTeX

@article{allodium:10.1016/j.eclinm.2023.102109,
  title = {Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.},
  author = {de Bruyn G and Wang J and Purvis A and Ruiz MS and Adhikarla H and Alvi S and Bonaparte MI and Brune D and Bueso A and Canter RM and Ceregido MA and Deshmukh S and Diemert D and Finn A and Forrat R and Fu B and Gallais J and Griffin P and Grillet MH and Haney O and Henderson JA and Koutsoukos M and Launay O and Torres FM and Masotti R and Michael NL and Park J and Rivera-Medina DM and Romanyak N and Rook C and Schuerman L and Sher LD and Tavares-Da-Silva F and Whittington A and Chicz RM and Gurunathan S and Savarino S and Sridhar S and VAT00002 booster cohorts study team},
  year = {2023},
  journal = {EClinicalMedicine},
  doi = {10.1016/j.eclinm.2023.102109},
  url = {https://doi.org/10.1016/j.eclinm.2023.102109}
}

RIS

TY  - JOUR
TI  - Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.
AU  - de Bruyn G
AU  - Wang J
AU  - Purvis A
AU  - Ruiz MS
AU  - Adhikarla H
AU  - Alvi S
AU  - Bonaparte MI
AU  - Brune D
AU  - Bueso A
AU  - Canter RM
AU  - Ceregido MA
AU  - Deshmukh S
AU  - Diemert D
AU  - Finn A
AU  - Forrat R
AU  - Fu B
AU  - Gallais J
AU  - Griffin P
AU  - Grillet MH
AU  - Haney O
AU  - Henderson JA
AU  - Koutsoukos M
AU  - Launay O
AU  - Torres FM
AU  - Masotti R
AU  - Michael NL
AU  - Park J
AU  - Rivera-Medina DM
AU  - Romanyak N
AU  - Rook C
AU  - Schuerman L
AU  - Sher LD
AU  - Tavares-Da-Silva F
AU  - Whittington A
AU  - Chicz RM
AU  - Gurunathan S
AU  - Savarino S
AU  - Sridhar S
AU  - VAT00002 booster cohorts study team
PY  - 2023
JO  - EClinicalMedicine
DO  - 10.1016/j.eclinm.2023.102109
UR  - https://doi.org/10.1016/j.eclinm.2023.102109
ER  -

APA

G, D. B., J, W., A, P., MS, R., H, A., S, A., MI, B., D, B., A, B., RM, C., MA, C., S, D., D, D., A, F., R, F., B, F., J, G., P, G., MH, G., O, H., JA, H., M, K., O, L., FM, T., R, M., NL, M., J, P., DM, R., N, R., C, R., L, S., LD, S., F, T., A, W., RM, C., S, G., S, S., S, S., & team, V. B. C. S. (2023). Safety and immunogenicity of a variant-adapted SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant as a booster in adults primed with authorized vaccines: a phase 3, parallel-group study.. EClinicalMedicine. https://doi.org/10.1016/j.eclinm.2023.102109

Source records